Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments

Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the company prepares to bring its ...

Why Structure Therapeutics (GPCR) Is Up 23.2% After Aleniglipron Milestone And $748 Million Raise – And What's Next

Structure Therapeutics recently reported strong Phase 2b results for its oral weight-loss candidate aleniglipron, secured a ...

Assessing Structure Therapeutics (GPCR) Valuation After Positive Phase 2 Data And Large Capital Raise

Structure Therapeutics (GPCR) has been in focus after reporting positive phase 2 results for its oral weight loss candidate ...

Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why

Structure Therapeutics Inc. (NASDAQ: GPCR) is among the 14 best booming stocks to buy right now. The company’s shares have ...

HC Wainwright upgrades Structure Therapeutics (GPCR) on massive arbitrage opportunity for oral GLP-1

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best up and coming stocks to buy according to Wall Street. On ...
Insider Monkey

Structure Therapeutics (GPCR) Hits 52-Week High on Weight Loss Treatment Trial

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to ...
Fintel on MSN

Structure Therapeutics Inc. - Depositary Receipt (GPCR) price target increased by 10.08% to 103.82

The average one-year price target for Structure Therapeutics Inc. - Depositary Receipt (NasdaqGM:GPCR) has been revised to ...

A 10% Owner Of Structure Therapeutics Shed Shares

A company controlled by the Johnson family sold thousands of shares of this clinical-stage biopharmaceutical company, but ...
Nasdaq

Citigroup Initiates Coverage of Structure Therapeutics Inc. - Depositary Receipt () (GPCR) with Buy Recommendation

Fintel reports that on May 2, 2025, Citigroup initiated coverage of Structure Therapeutics Inc. - Depositary Receipt () (NasdaqGM:GPCR) with a Buy recommendation. As of April 24, 2025, the average one ...